2025
Phase 1/2 study of zilovertamab vedotin in pediatric and young adult hematologic malignancies or solid tumors (LIGHTBEAM-U01A).
Kang H, Berlanga P, Campbell-Hewson Q, DuBois S, Koh K, Mauz-Körholz C, Sullivan M, Mangum D, Windsor R, Dickens D, Duarte A, Pashankar F, Ash S, Bellantoni A, Diede S, Singh R, Sidi Y, Yalon M. Phase 1/2 study of zilovertamab vedotin in pediatric and young adult hematologic malignancies or solid tumors (LIGHTBEAM-U01A). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps10075.Peer-Reviewed Original ResearchB-cell acute lymphoblastic leukemiaEwing sarcomaPerformance statusAdverse eventsPediatric B-cell acute lymphoblastic leukemiaRefractory to frontline therapyDose of study treatmentDiagnosis of B-cell acute lymphoblastic leukemiaEnd pointsObjective response ratePhase 1/2 studyRadiographically measurable diseaseBone marrow blastsDuration of responseECOG performance statusSecondary end pointsPrimary end pointAdult hematological malignanciesAcute lymphoblastic leukemiaKarnofsky performance statusAntibody-drug conjugatesDose escalationMarrow blastsFrontline therapyOpen-label
2019
Identification of ZNF217 As an Essential Oncogenic Gene in B-Cell Acute Lymphoblastic Leukemia By CRISPR/Cas9-Based Library Screening
Qin X, Su R, Yang L, Chan A, Deng X, Qing Y, Klemm L, Müschen M, Chen C, Chen J. Identification of ZNF217 As an Essential Oncogenic Gene in B-Cell Acute Lymphoblastic Leukemia By CRISPR/Cas9-Based Library Screening. Blood 2019, 134: 1465. DOI: 10.1182/blood-2019-129849.Peer-Reviewed Original ResearchB-cell acute lymphoblastic leukemiaBCR-ABL1 fusionAcute lymphoblastic leukemiaAcute myeloid leukemiaAML cellsM6A regulatorsMLL-AF4 fusionAdult patientsLymphoblastic leukemiaPediatric B-cell acute lymphoblastic leukemiaEssential oncogenic roleM6A modificationMessenger RNACytogenetic characteristicsDismal survivalMyeloid leukemiaB cell progenitorsTherapeutic targetOncogenic roleSolid tumorsPatientsZinc finger protein 217B-lineageLeukemiaCytogenetic changes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply